The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +5.17% 3-day Advance, the price is estimated to grow further. Considering data from situations where NKTX advanced for three days, in 210 of 249 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
NKTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on September 25, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NKTX as a result. In 72 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
NKTX moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for NKTX crossed bearishly below the 50-day moving average on October 07, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 79%.
The 50-day moving average for NKTX moved below the 200-day moving average on October 21, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NKTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for NKTX entered a downward trend on October 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 38 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.451) is normal, around the industry mean (3.162). P/E Ratio (-0.981) is within average values for comparable stocks, (-1.064). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.622) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. NKTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NKTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where VANI declined for three days, in 249 of 293 cases, the price declined further within the following month. The odds of a continued downward trend are 85%.
The Momentum Indicator moved below the 0 level on October 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VANI as a result. In 71 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.
The 50-day moving average for VANI moved below the 200-day moving average on October 29, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where VANI's RSI Oscillator exited the oversold zone, 19 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 68%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 65 cases where VANI's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
The Moving Average Convergence Divergence (MACD) for VANI just turned positive on October 28, 2026. Looking at past instances where VANI's MACD turned positive, the stock continued to rise in 37 of 50 cases over the following month. The odds of a continued upward trend are 74%.
Following a +2.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where VANI advanced for three days, in 158 of 209 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
VANI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 23 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 69 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.184) is normal, around the industry mean (3.162). P/E Ratio (-3.028) is within average values for comparable stocks, (-1.064). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.622) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 75 (best 1 - 100 worst), indicating slightly worse than average price growth. VANI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VANI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
NKTX | VANI | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 38 Fair valued | 69 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 97 | 100 | |
PRICE GROWTH RATING 1..100 | 86 | 75 | |
P/E GROWTH RATING 1..100 | 13 | 23 | |
SEASONALITY SCORE 1..100 | 50 | 37 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NKTX's Valuation (38) in the null industry is in the same range as VANI (69). This means that NKTX’s stock grew similarly to VANI’s over the last 12 months.
NKTX's Profit vs Risk Rating (100) in the null industry is in the same range as VANI (100). This means that NKTX’s stock grew similarly to VANI’s over the last 12 months.
NKTX's SMR Rating (97) in the null industry is in the same range as VANI (100). This means that NKTX’s stock grew similarly to VANI’s over the last 12 months.
VANI's Price Growth Rating (75) in the null industry is in the same range as NKTX (86). This means that VANI’s stock grew similarly to NKTX’s over the last 12 months.
NKTX's P/E Growth Rating (13) in the null industry is in the same range as VANI (23). This means that NKTX’s stock grew similarly to VANI’s over the last 12 months.
| NKTX | VANI | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 85% | 4 days ago 68% |
| Stochastic ODDS (%) | 5 days ago 83% | 4 days ago 75% |
| Momentum ODDS (%) | 7 days ago 89% | 4 days ago 78% |
| MACD ODDS (%) | N/A | 4 days ago 74% |
| TrendWeek ODDS (%) | 4 days ago 87% | 4 days ago 80% |
| TrendMonth ODDS (%) | 4 days ago 87% | 4 days ago 81% |
| Advances ODDS (%) | 8 days ago 84% | 7 days ago 76% |
| Declines ODDS (%) | 4 days ago 89% | 18 days ago 85% |
| BollingerBands ODDS (%) | 4 days ago 83% | 4 days ago 89% |
| Aroon ODDS (%) | 4 days ago 85% | N/A |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
NKTX’s FA Score shows that 1 FA rating(s) are green while VANI’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
NKTX’s TA Score shows that 4 TA indicator(s) are bullish while VANI’s TA Score has 5 bullish TA indicator(s).
NKTX (@Biotechnology) experienced а -12.85% price change this week, while VANI (@Biotechnology) price change was -1.80% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +0.20%. For the same industry, the average monthly price growth was -14.01%, and the average quarterly price growth was -15.33%.
NKTX is expected to report earnings on Nov 09, 2026.
VANI is expected to report earnings on Nov 12, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, NKTX has been loosely correlated with EDIT. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if NKTX jumps, then EDIT could also see price increases.
| Ticker / NAME | Correlation To NKTX | 1D Price Change % | ||
|---|---|---|---|---|
| NKTX | 100% | -6.02% | ||
| EDIT - NKTX | 49% Loosely correlated | -8.87% | ||
| CRSP - NKTX | 46% Loosely correlated | -5.23% | ||
| VIR - NKTX | 46% Loosely correlated | -3.83% | ||
| RCKT - NKTX | 44% Loosely correlated | -3.94% | ||
| RNAC - NKTX | 43% Loosely correlated | -3.85% | ||
More | ||||
A.I.dvisor indicates that over the last year, VANI has been loosely correlated with VTVT. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if VANI jumps, then VTVT could also see price increases.
| Ticker / NAME | Correlation To VANI | 1D Price Change % | ||
|---|---|---|---|---|
| VANI | 100% | -4.39% | ||
| VTVT - VANI | 60% Loosely correlated | -4.59% | ||
| AZR - VANI | 37% Loosely correlated | -20.79% | ||
| AXSM - VANI | 36% Loosely correlated | +0.68% | ||
| NKTX - VANI | 34% Loosely correlated | -6.02% | ||
| SCNI - VANI | 34% Loosely correlated | -9.05% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| CEMB | 44.12 | 0.03 | +0.06% |
| iShares J.P. Morgan EM Corporate Bond ETF (CEMB) | |||
| CPSO | 28.45 | -0.10 | -0.35% |
| Calamos S&P 500 Structured Alt Protection ETF - October (CPSO) | |||
| USPX | 65.98 | -1.25 | -1.87% |
| Franklin U.S. Equity Index ETF (USPX) | |||
| GNOM | 69.61 | -2.93 | -4.04% |
| Global X Genomics & Biotechnology ETF (GNOM) | |||
| WDIG | 32.80 | -2.38 | -6.75% |
| WisdomTree Efficient Rare Earth Plus Strategic Metals Fund (WDIG) | |||